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Cancer/Testis (CT) antigens are normally only expressed in germ cells 
and yet are aberrantly activated in a wide variety of human cancers. 
Most chromosome X-encoded CT antigens (CT-X) show restricted 
expression in pre-meiotic germ cells in adult testis, except for the 
expression of SPANX in post-meiotic germ cells. In the present study, 
the expression of eight CT-X antigens (MAGE-A, NY-ESO-1, GAGE, 
MAGE-C1/CT7, MAGE-C2/CT10, CT45, SAGE1, and SPANX) in 
non-seminomatous germ cell tumors was evaluated immunohis-
tochemically, including 24 embryonal carcinomas, 20 yolk sac tumors, 
9 teratomas, and 3 choriocarcinomas, and the results were compared 
to our previous study of 77 classic seminomas and 2 spermatocytic 
seminomas. SPANX was not detected in any germ cell tumors tested. 
Spermatocytic seminoma showed strong expression of all CT-X anti-
gens tested (except SPANX), reflecting their origin from adult CT-X-
positive pre-meiotic germ cells. Classic seminomas, originating from 
prenatal gonocytes, showed widely variable frequency of CT-X anti-
gen expression, ranging from > 80% (CT7, CT10, CT45, and GAGE), 
63% (MAGE-A), 18% (NY-ESO-1) to only 4% (SAGE1). In compari-
son, non-seminomatous germ cell tumors expressed CT-X antigens 
much less frequently and usually only in small subsets of tumor cells. 
Intratubular germ cell neoplasia (ITGCN) were mostly CT-X-negative, 
even in CT-X positive classic seminomas. These findings indicate that 
CT-X antigens are not expressed in the fetal precursor cells for germ 
cell tumors, and their expression likely reflects germ cell differentia-
tion of the neoplastic cells (in seminomas) or aberrant gene activation 
as cancer antigens (in non-seminomatous tumors).
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Introduction
Cancer/Testis (CT) antigens were initially identified during 
the search for immunogenic tumor antigens capable of elicit-
ing spontaneous immune responses in cancer patients. MAGE, 
BAGE, and GAGE antigens (1), the first group of tumor antigens 
shown to elicit cell-mediated immune responses in melanoma 
patients, were found to have their mRNA expression limited to 
testis, and no expression in any other normal adult tissue was 
detected. Subsequent serological cloning of antigens that elicited 
antibody responses in cancer patients identified SSX, NY-ESO-1, 
and CT7, all of which also share this distinctive characteristic of 
testis-restricted expression and aberrant activation in various 
types of human cancer. This unique feature led us to designate 
this group of antigens as CT antigens (2, 3), and clinical trials 
using CT antigens as cancer vaccine targets are ongoing (4-6).
The distinctive CT mRNA expression pattern also provided 
in silico analytic tools and led to subsequent identification of 
many novel genes with similar characteristics, and the num-
ber of CT and CT-like genes in the literature expanded from 
20 in 2002 (7), 44 in 2004 (8), to more than 110 in the most 
recent version of CTpedia (9, 10), a CT-database established by 
the Ludwig Institute for Cancer Research (11). These genes can 
be separated into two main groups. The first group consists of 
genes on non-X chromosomes, many of them encoding pro-
teins with known biological functions either in spermatids or 
in the process of spermatogenesis, including ACRBP (acrosin-
binding protein), ADAM2, and meiotic proteins SCP1, SYCE, 
and HORMAD1 (12-14). Most of these genes are expressed 
during or after meiosis, but not in the pre-meiotic spermatogo-
nia or spermatocytes. In contrast, the second group comprises 
approximately 30 genes (or gene families) on X chromosome, 
most of them encoding proteins with unknown functions. 
These genes have been referred to as CT-X genes (3, 10). 
By immunohistochemical studies, we recently showed that 
most of these genes, including MAGE-A, NY-ESO-1, GAGE, 
CT7, CT10, CT45, and SAGE1, are expressed in spermatogo-
nia and/or primary spermatocytes in adult testis, but not in 
post-meiotic germ cells. The only exception to this rule is the 
SPANX gene family that encodes proteins that are involved in 
the morphogenesis of mature sperm cells and are expressed 
in spermatids and sperm cells (15, 16). 
In fetal testis, all germ cells are derived from OCT3/4-positive 
primordial germ cells (PGCs). As these OCT3/4-positive pluri-
potent cells migrate to the gonads from the dorsal yolk sac and 
develop into germ cells, the expression of OCT3/4 is lost (17-19). 
By immunohistochemical analysis, we recently showed that the 
expression of OCT3/4 and CT-X antigens are almost always mutu-
ally exclusive, and CT-X expression in fetal testis only appears 
when fetal testicular gonocytes have lost OCT3/4 expression 
and committed to spermatogenesis (20). This finding of CT-X 
antigen expression in fetal testicular germ cells, possibly includ-
ing primordial germ cells, raises the possibility that CT-X anti-
gens might be frequently expressed in germ cell tumors (GCTs). 
Although several studies have investigated this issue, the analyses 
were limited to one or two CT antigens, e.g., MAGE-A (21-24), 
NY-ESO-1(25), SSX (26), GAGE (27), and CT45 (28), and the 
results were discrepant, particularly in terms of their expression 
in non-seminomatous germ cell tumors and in intratubular germ 
cell neoplasia (ITGCN). We recently evaluated the expression of 
multiple CT antigens in fetal gonads and in seminoma (20), and 
we have now expanded this study to non-seminomatous germ cell 
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tumors (NSGCTs) to explore the possible differential expression 
of CT antigens in this heterogeneous group of tumors that might 
reflect different mechanisms of gene activation and evaluate their 
potential values as diagnostic markers or therapeutic targets.
Results
Of the eight CT-X antigens (MAGE-A, NY-ESO-1, GAGE, 
CT7, CT10, CT45, SAGE1, and SPANX) examined, no SPANX 
expression was identified in any germ cell tumors. In compari-
son, all seven other CT-X antigens were expressed at variable 
frequencies in different types of germ cell tumors, more abun-
dantly in spermatocytic seminomas and classic seminomas, as 
previously reported (20). Non-seminomatous germ cell tumors 
expressed CT-X antigens at variable but in general much lower 
frequencies, and these results are summarized in Table 1 in con-
junction with the previous results on seminomas.
Embryonal carcinoma
In comparison to seminomas, embryonal carcinoma showed 
no or minimal expression of CT-X antigens. Of 24 embryo-
nal carcinomas, 10 were totally negative for all CT-X antigens 
and 11 showed positivity in a very small subset of tumor cells, 
comprising < 1% of the tumor cells in most cases. The only excep-
tion to this very focal pattern of CT-X expression was seen in a 
case of mixed germ cell tumors that contained yolk sac tumor, 
choriocarcinoma, and embryonal carcinoma components. In 
this particular case, GAGE expression was observed in all three 
components, including in > 90% of the embryonal carcinoma 
component (Figure 1). The other 7 CT antigens tested were all 
negative in the embryonal carcinoma component.
Among the eight CT-X antigens analyzed, GAGE was most 
frequently expressed in embryonal carcinomas, observed in 
10 of 24 (42%) cases. Other CT-X antigens were only expressed 
in 4% to 21% of cases, all in extremely focal patterns.
Yolk sac tumor
Among non-seminomatous GCTs, yolk sac tumors showed 
most frequent expression of CT-X antigens. Twenty yolk sac 
tumors were examined, including 3 pediatric yolk sac tumors, 
and CT-X expression was detected in 12 (60%) cases, 9 of them 
expressing 3 or more CT-X antigens. Two of the three pediatric 
yolk sac tumors were CT-X-positive but expressed only CT45 
and not any other CT-X antigens. The extent of positivity is 
highly variable, from < 1% of tumor cells being positive to dif-
fuse positivity in 80-100% of the tumor cells (Figure 2).
Among the CT-X antigens, CT45, CT7, and MAGE-A were most 
frequently expressed in adult yolk sac tumors, detected in 59%, 
43%, and 47% of cases, respectively. In comparison, CT10, GAGE, 
SAGE1, and NY-ESO-1 were expressed in 24-35% of the cases. 
Teratoma
A component of mature or immature teratoma was identi-
fied in nine cases as part of mixed non-seminomatous germ 
cell tumor. These teratoma components showed either no CT-X 
expression (5/9) or minimal (4/9) expression in < 1% of the 
tumor cells. In one of the 4 positive cases, the same small cluster 
of cells were found to co-express MAGE-A, CT7, GAGE, and 
NY-ESO-1 (Figure 3). The other three cases were positive for 
one to three CT-X antigens. 
Figure 1
Expression of CT-X antigens in embryonal carcinoma. Examples of MAGE-A 
(A), NY-ESO-1 (B), GAGE (C), and CT7 (D) expression are shown, illustrat-
ing the highly focal nature of CT-X expression in embryonal carcinoma, the 
only exception being the expression of GAGE in a case of mixed germ cell 
tumor with embryonal carcinoma component (C). (Magnification, 200X).
Choriocarcinoma
Only three choriocarcinomas were in this series and two of 
three were CT-X antigen-positive. One case showed expression 
of GAGE, MAGE-A, CT10, and CT45, but in highly variable 
Table 1
Expression of CT-X antigens in germ cell tumors.
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percentages of cells, estimated to be 90%, 30%, < 5%, and < 2%, 
respectively (Figure 4). Positive staining was observed in both 
cytotrophoblasts and syncytiotrophoblasts. The other case was 
only positive for CT45, detected in about 40% of the tumor 
cells.
Intratubular germ cell neoplasia (ITGCN)
CT-X-positive germ cells were often identified in atrophic semi-
niferous tubules adjacent to the germ cell tumors regardless of the 
CT-X expression status of the main tumor. Whether these repre-
sent ITGCN or residual spermatogonia or both could be difficult 
to distinguish histologically (Figure 5A vs. 5C). To separate resid-
ual non-neoplastic spermatogonia from ITGCN, OCT3/4 was 
used to define ITGCN and possible co-expression of CT-X was 
evaluated by double-staining of OCT3/4 and CT7, or OCT3/4 
and MAGE-A. CT7 shows cytoplasmic staining in spermatogonia 
and MAGE-A is present as both nuclear and cytoplasmic stain-
ing, allowing their detection in ITGCN cells with nuclear OCT3/4 
positivity (Figure 5B and 5D).
These double-staining experiments showed that the majority 
(14/18, 78%) of ITGCN were negative for CT7 (or MAGE-A) 
expression, including 5 cases in which the invasive component 
was CT7 (or MAGE-A)-positive. An example of this is shown in 
Figure 5E and 5F. As illustrated, ITGCN often co-existed with 
non-neoplastic spermatogonia in the same tubules, evidenced 
by their positive CT7 (Figure 5B, 5F, and 5G) or MAGE-A 
(Figure 5H) staining. Exceptions to this negative expression of 
CT-X in ITGCN cells, however, were observed in two cases each 
for CT7 and MAGE-A in which occasional OCT3/4 and CT7 
(or MAGE-A) dual-positive cells were identified (Figure 5G and 
5H), co-existing with OCT3/4-positive and CT7 (or MAGE-A)- 
negative ITGCN cells. 
Intratubular spematocytic seminoma
In contrast to the rare expression of CT-X antigens in ITGCN, 
the intratubular component of the spermatocytic seminoma 
that is present in one of the two cases expressed all seven CT-X 
antigens in a homogeneous manner, similar to its invasive com-
ponent (Figure 6). 
Discussion
Germ cell tumors originate from germ cells at different stages 
of maturation and most of the phenotypic characteristics found 
in this heterogeneous group of tumors are believed to reflect 
the gene expression profile at that specific stage of germ cell 
development. Oosterhius and Looijenga (29) proposed a clas-
sification scheme that separated GCTs into 5 types based on 
this notion. Type I GCTs, the teratomas and yolk sac tumors 
seen in neonates and childhood, presumably derived from early 
primordial germ cell (PGC) or gonocytes. Type II GCTs, adult 
seminomatous and non-seminomatous GCTs, including most 
testicular GCTs, are believed to originate from PGC/gonocytes 
in utero, but at a maturation stage slightly later than the type I 
precursors, evidenced by the erased pattern of genomic imprint-
ing in these tumors. The only adult testicular GCT that does not 
belong to type II is spermatocytic seminoma, which originates 
from adult pre-meiotic germ cells rather than prenatal PGC/
gonocytes and is classified as type III. Dermoid cyst of the ovary 
and hydatiform mole of pregnancy represent special categories 
of GCTs from oogonia/oocyte and empty ovum/spermatozoa, 
respectively, and are classified as types IV and V.
This concept that different GCTs originate from germ cells at 
different stages of maturation is best supported by the different 
gene expression profiles of classic seminoma and spermatocytic 
seminoma. Seminomas express markers typically seen in embry-
onic stem cells and PGCs, including OCT3/4, c-KIT, PLAP, and 
NANOG (18, 30). In contrast, spermatocytic seminomas have 
completely lost these markers of pluripotency and express mark-
ers characteristic of spermatogenesis, including CT antigens. 
This difference was convincingly shown in the mRNA expression 
microarray study by Looijenga et al. (31) in which CT antigen 
genes GAGE, SSX, MAGE, SAGE, and BORIS all showed 20- to 
100-fold higher expression in spermatocytic seminoma than in 
seminomas, and OCT3/4 and NANOG were 100-fold higher in 
seminomas. Previous protein expression studies by immuno-
histochemistry confirmed the lack of OCT3/4 and NANOG in 
spermatocytic seminoma (18, 19, 32) and the universal expres-
sion of SSX [in 13 of 13 cases by Stoop et al. (26)] and MAGE-A 
Figure 2
Figure 3
Expression of CT-X antigens in yolk sac tumor. Examples of MAGE-A (A), 
CT45 (B), CT7 (C), and SAGE1 (D) expression are shown. The expression pattern 
is patchy in most cases, but often positive in a larger proportion of tumor cells when 
compared to CT-X antigen-positive embryonal carcinomas. (Magnification, 200X).
Expression of  CT-X antigens in a case of teratoma. Teratomas are rarely positive, but 
one case was positive for MAGE-A (A), CT7 (B), GAGE (C), and NY-ESO-1 (D). The 
same small clusters of positive cells (< 1% of the tumor) were noted to simultaneously 
express these CT-X antigens in a CT-X-negative background. (Magnification, 200X).
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[in 25 of 25 cases by Rajpert-De Meyts et al. (24)] in spermato-
cytic seminoma. Supporting these prior findings and expanding 
on our recent study (20), we now found that all pre-meiotically 
expressed CT-X proteins, including GAGE, SAGE, NY-ESO-1, 
CT7, CT10, and CT45, are diffusely expressed in spermatocytic 
seminomas, including in the intratubular in situ component. This 
finding supports the notion that spermatocytic seminomas are 
derived from CT-positive pre-meiotic adult germ cells. With the 
exception of CT10 and CT45 that show strongest expression in 
primary spermatocytes (27, 30), all antigens above have stron-
gest expression in spermatogonia, indicating that spermatocytic 
seminomas likely originate from spermatogonia, as was previ-
ously proposed (24). However, since all CT-X antigens examined 
in the study are expressed at both spermatogonia and primary 
spermatocytes stages, albeit at different levels, it remains pos-
sible that spermatocytic seminomas can originate from pri-
mary spermatocytes (31). Different from these finding of 100% 
CT-X expression in spermatocytic seminoma, however, Satie et 
al. (25) detected NY-ESO-1 expression in only 8 of 16 sperma-
tocytic seminomas. This less frequent expression of NY-ESO-1 
might reflect the fact that all spermatogonia, while positive for 
MAGE-A, are not NY-ESO-1-positive (20, 33). Alternatively, the 
absence of NY-ESO-1 expression in some spermatocytic semi-
nomas in their study might be due to a lower sensitivity in their 
immunohistochemical detection of NY-ESO-1, as different anti-
bodies were used in their and our studies.
In contrast to the expression of almost all CT-X antigens in the 
intratubular spermatocytic seminomas, the in situ precursors of 
all testicular seminomatous and non-seminomatous germ cell 
tumors, ITGCN cells, were mostly CT-negative in our study, even 
when the corresponding invasive tumors were CT-positive. This 
finding was also observed by Stoop et al. (26) who noted that 
ITGCN cells in all three SSX-positive seminomas in their series 
were SSX-negative. In contrast to this finding, however, were 
studies that found ITGCN cells to be at least partially positive for 
MAGE-A in 13 of 15 cases (21), for NY-ESO-1 in 7 of 15 cases 
(25), and for CT45 expression in most, if not all, cases (28). This 
reason for this discrepancy in the prevalence of CT-X expression 
in ITGCN is not entirely clear. One main difference between the 
current and the earlier studies, however, was that we defined our 
ITGCN population by positive OCT3/4-positive, rather than rely-
ing on histological criteria alone. We found this to be necessary 
as atrophic tubules adjacent to the GCTs often contain residual 
spermatogonia that are histologically almost indistinguishable 
from ITGCN cells (Figure 5A vs. 5C). Based on this observa-
tion, we suspect that at least some of the CT-positive ITGCN 
cases described in the earlier literature might represent residual 
benign spermatogonia in atrophic tubules, and not ITGCN cells. 
Combining our data with those of earlier studies, we believe that 
ITGCN cells could be either CT-X-positive or -negative, and 
these two populations can co-exist in the same case. Since the 
Figure 5
Expression of CT-X antigens in ITGCN. Seminiferous tubules in two different cases 
of seminoma showed possible ITGCN (A and C). Using OCT3/4 (nuclear, brown) 
and CT7 (cytoplasmic, red) dual staining, one case (B) showed ITGCN with mutu-
ally exclusive expression between CT7-negative; OCT3/4-positive ITGCN cells; 
and CT7-positive, OCT3/4-negative residual spermatogonia in the same tubules, 
whereas the other case (D) showed only spermatogonia (i.e., CT7-positive, OCT3/4-
negative), negative for ITGCN. The invasive component of this second tumor (D, 
on the right) was OCT3/4-positive and CT7-negative. In most CT-X positive cases 
(E, a case of CT7-positive mixed embryonal carcinoma and yolk sac tumor), the 
ITGCN component (F, OCT3/4-positive cells in brown) was negative for CT-X 
expression (CT7, red). However, CT-X-positive ITGCN cells could be identified in 
some cases, evidenced by co-expression of OCT3/4 and CT7 (E) [or OCT3/4 and 
MAGE-A (F)], co-existing with CT-X-negative ITGCN cells. (Magnification, 400X). 
Figure 4
Expression of CT-X antigens in a case of choriocarcinoma. Heterogeneous 
staining patterns were observed, more diffusely positive for GAGE (A) 
and MAGE-A (B) than for CT45 (C) and CT10 (D). Both syncytiotropho-
blasts and cytotrophoblasts were MAGE-A-positive. (Magnification, 200X).
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precursors of type II GCTs are OCT3/4-positive pluripotent 
PGC/gonocytes that normally would be CT-X antigen-negative, 
it is most likely that early ITGCN cells are CT-X-negative, which 
subsequently become CT-X antigen-positive in some, but not all, 
cases. One likely explanation for this gain of CT expression would 
be the partial differentiation of tumor cells along the pathway of 
spermatogenesis. Since seminoma represents a differentiation of 
ITGCN cells toward germ cell lineage (29, 34), it is fully conceiv-
able that CT antigen expression can be switched on during this 
differentiation process, either during the in situ stage or in the 
subsequent invasive phase. This concept is corroborated by two 
findings in our current study. One is the much more frequent 
expression of CT antigens in seminoma than in GCTs that are 
either undifferentiated, i.e., embryonal carcinomas, or differen-
tiated towards somatic lineages, i.e., teratomas. The other is the 
highly variable expression frequency for individual CT antigen in 
seminomas, ranging from > 80% (CT7, CT10, CT45, and GAGE) 
to < 5% (SAGE) or negative (SPANX). This cascade of CT expres-
sion frequency in seminoma, high in CT7 and GAGE and low 
in SAGE, roughly correlates with the relative abundance of these 
CT-X antigens in developing fetal germ cells (20) and suggests 
a parallel germ cell differentiation process in both benign and 
malignant germ cells. The high frequency of CT45 expression in 
classic seminoma (92%) that we observed confirmed the findings 
of Rudolph et al. (100% in 55 cases), and the lower frequency 
of MAGE-A expression (63%) in our data also falls within the 
previously described frequency of 42%-71% (21-23). However, 
NY-ESO-1, observed in 18% (14/76) of our cases, was not 
detected in any of the 13 cases previously analyzed by Satie et 
al. (25). The reason for this discrepancy is unclear but it is likely 
attributable to our larger sample size and/or to the different sensi-
tivity of the anti-NY-ESO-1 antibodies used in these two studies. 
In contrast to seminomas, expression of CT-X antigens in 
non-seminomatous GCTs cannot be explained by this notion 
of germ cell differentiation, and two other mechanisms could 
be postulated. One is the aberrant epigenetic activation of CT-X 
genes as cancer antigens similar to their activation in non-germ 
cell malignancy and the other is that some non-seminoma-
tous GCTs might have foci of tumor cells that have retained 
or acquired partial germ cell features, resulting in their CT-X 
positivity. Which one of the two mechanisms (or both) is at play 
is unknown to us at present. Although additional studies, e.g., 
methylation studies of the promoter regions of these CT genes, 
might help to clarify this, the highly focal nature of CT expres-
sion in these tumors would mean that laser microdissection is 
necessary to separate CT-negative from CT-positive areas for 
such experiments. Given this technical challenge and the quan-
titative nature of the methylation assays, whether this approach 
could unequivocally distinguish these two possible mechanisms 
is uncertain. It is clear, however, that either mechanism only 
occurs rather infrequently, as indicated by the much lower fre-
quency of CT-X expression in non-seminomatous GCTs, as well 
as the focal and often patchy expression pattern in individual 
tumor. In fact, two previous studies showed no MAGE-A4 
expression in 10 cases of non-seminomatous GCTs (21) and no 
NY-ESO-1 expression in 13 cases (25), leading to the notion that 
CT-X genes are always silent in these tumors. With a larger series 
of samples, we now know that CT-X antigens can be expressed in 
non-seminomatous GCTs, albeit at significantly lower frequen-
cies than in seminomas. Our observation of CT-X expression 
in non-seminomatous GCTs is also supported by the previously 
described expression of CT45 in about 50% of yolk sac tumor 
(28) and GAGE expression in a teratoma (27). Similarly, mRNA 
studies (35) have demonstrated CT expression in various types 
of NSGCTs, including yolk sac tumor, embryonal carcinoma, 
and mixed NSGCTs. Of interest, yolk sac tumors, either from 
pediatric or adult patients, appear to express CT-X antigens 
more frequently than other types of non-seminomatous GCTs 
[(28) and the present study], suggesting that the second mecha-
nism (of retained gonocyte phenotype) described above might 
be involved in this specific tumor type.
In summary, CT antigens, normally expressed in pre-sper-
matogonia in fetal testis and in spermatogonia and pre-meiotic 
spermatocytes in adult, are expressed most frequently in sper-
matocytic seminomas, less in classic seminomas, and least in 
NSGCTs. Given their overlapping expression patterns in these 
tumors, CT antigens are not useful diagnostic markers for GCTs. 
However, their expression at a significant proportion of GCTs 
does suggest CT antigens as candidates for targeted therapy for 
GCTs. Biologically, our findings indicate three distinctive mech-
anisms of CT gene activation. In spermatocytic seminoma, CT 
expression reflects the intrinsic characteristics of the precursor 
adult pre-meiotic germ cells and the expression is most homoge-
neous in pattern. In classic seminoma, CT expression is acquired 
as a result of germ cell differentiation, likely from CT-negative 
ITGCN cells. In NSGCTs, CT expression is likely due to epige-
netic aberrant activation or retained gonocyte phenotype, and 
this would account for the heterogeneous and often focal CT-X 
antigen expression pattern in these tumors. 
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Materials and methods
Tissues
Formalin-fixed paraffin-embedded tissue blocks of nor-
mal and tumor tissues were obtained from the Department of 
Pathology and Laboratory Medicine at Weill Cornell Medical 
College and Washington University School of Medicine follow-
ing protocols approved by the two Institutional Review Boards 
(IRB). All hematoxylin and eosin stained tissue sections were 
evaluated and the diagnoses of seminoma and various compo-
nents of NSGCTs were confirmed.
Monoclonal and polyclonal antibodies
The antibodies used are summarized in Table 2. Antibodies 
against GAGE, SAGE1, MAGE-A, and SPANX were purchased 
commercially. GAGE antibody produced against GAGE-7 is 
expected to react with all GAGE gene products due to the extreme 
Table 2
Anti-CT-X antibodies used in the present study.
8 of 8 www.cancerimmunity.org
Cancer Immunity (10 May 2013), Vol. 13, p. 10
high sequence homology among the GAGE proteins. MAGE-A 
monoclonal antibody 6C1 produced against MAGE-A1 has 
been shown to be broad-reactive for gene products of MAGE-A 
multigene family, including MAGE-A1, A2, A3, A4, A6, A10, 
and A12 protein (36). SPANX antibody, obtained commercially, 
was produced against SPANX-C. However, due to the polyclonal 
nature of this antibody, it is highly likely that this antibody would 
also recognize SPANX-A and SPANX-B proteins. Antibodies 
against the other CT-X antigens NY-ESO-1, CT7, CT10, and 
CT45 were produced and characterized in our laboratory and 
have been previously described (37-40). 
Immunohistochemical analysis
Immunohistochemical (IHC) analysis was performed using 
formalin-fixed paraffin-embedded tissues. Whole sections were 
used for non-seminomatous germ cell tumors, and expression 
in seminoma was evaluated using a tissue microarray (TMA), 
each case represented by three 0.6 mm tissue cores. Selective 
cases of seminoma were also evaluated on whole sections for the 
evaluation of ITGCN. Five µM tissue sections on coated slides 
were deparaffinized, rehydrated, and treated in H2O2 to block 
the endogenous peroxidase activity. The sections were then sub-
jected to antigen retrieval by autoclaving for 15 minutes in 10 
mM citrate buffer, pH 6.0. The sections were incubated with the 
primary antibody for one hour at room temperature, followed by 
detection using Dako EnVision+ horseradish peroxidase mouse 
(or rabbit) detection system (DakoCytomation) and DAB as the 
chromogen. The slides were counterstained with hematoxylin 
and evaluated. Any staining of the tumor cells is regarded as 
positive, and positive immunoreactivity was recorded as + to 
+++ based on the staining intensity. The staining pattern, either 
focal (< 50%) or diffuse (> 50%), was also recorded. Adult testis 
was used as positive control and immunoglobulin isotype con-
trols were also included in all experiments.
For double immunostaining, the first antibody staining was 
performed as above, using DAB as chromogen. After DAB 
chromogen reaction, the slides were washed with Tris-buffered 
saline pH 7.0, blocked by Dual Endogenous Enzyme Block 
(DakoCytomation), and incubated with the second antibody for 
30 minutes at room temperature, followed by detection using 
LSAB 2 System-Alkaline Phosphatase (DakoCytomation) and 
developed by Permanent Red chromogen. The slides were then 
counterstained and scored as described above. 
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